Skip to main content
Equibles
VNRX logo

VNRX · Volitionrx Ltd · Metrics

Track VNRX — free

Use VNRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VNRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.17 0.00 (-0.12%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Customer concentration — top 2 customers 38% of receivables

2 customers — 38% of receivables (At December 31, 2025)

“At December 31, 2025 the two largest customer balances represented over 38% of the total outstanding accounts receivable balance.”
View the 10-K filed Mar 31, 2026
Market Cap
$2.33M
Shares
13.65M
Volume · Oct 20 593.17K Avg daily vol (3M) 8.45M

VNRX metrics

64 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.17
Market cap
$2.33M

Price action

20 metrics
Price change (1W)
-6.2%
Price change (30D)
-34.6%
Price change (3M)
-84.4%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
119.5%
Annualized volatility (3M)
128.0%
Beta
2.8
RSI (14D)
23.2
Price vs SMA 50
-47.6%
Price vs SMA 200
—
Avg volume (3M)
8.45M
Relative volume
0.1
Average dollar volume
$3.83M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
13.65M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.7×
reciprocal yield 37.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.9×
reciprocal yield 105.6%
P / book
—
FCF yield
-841.0%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,098.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
57.4×
reciprocal yield 1.7%
EV / revenue historical average (5Y)
385.4×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
-790.2%
Trailing 12 months
Net margin
-1,041.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$19.42M
Net income (TTM)
−$25.59M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-796.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-5.45

Growth

11 metrics
Revenue growth YoY
-2.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.46M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+78.4%
Year over year · more shares
Revenue CAGR (3Y)
+78.0%
Revenue CAGR (5Y)
+164.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-308.2%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
−$18.55M
Free cash flow (TTM)
−$19.58M
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$4.25M
Latest balance sheet
Cash & equivalents
$2.80M
Total assets
$8.30M
Total debt
$7.05M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.56M
Capital expenditures (TTM)
$21,969
R&D (TTM)
$9.41M
SG&A (TTM)
—
Stock compensation (TTM)
$939,277
R&D / revenue
382.7%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
24
13F filer change QoQ
-7
Institutional ownership
14.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
2.5%
Private-fund adviser ownership
0.2%
Active holders' share change QoQ
+90.2%
Holder tenure
21.6
Price vs estimated holder cost
-92.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.7%

Short interest

3 metrics
Short interest
8.8%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
52 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 93314 CUSIP 928661206 13F (30d) 4 filings 4 filers Visit website Investor relations